Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer

被引：0
|
作者：
Abraham, Jame
Mechcatie, Elizabeth
机构：
来源：
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY | 2015年 / 13卷 / 03期
关键词：
D O I：
10.12788/jcso.0113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：83 / 86
页数：4
相关论文
共 50 条
  • [21] Mechanisms of primary AI resistance in ER-positive HER2-negative breast cancer.
    Miura, Daishu
    Iwatani, Tsuguo
    Kawabata, Hidetaka
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
    Ueno, Takayuki
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [23] Reply to: Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer
    Goldhirsch, A.
    Coates, A. S.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 755 - 755
  • [24] The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features
    Salaun, Helene
    Djerroudi, Lounes
    Haik, Laura
    Schnitzler, Anne
    Bataillon, Guillaume
    Deniziaut, Gabrielle
    Bieche, Ivan
    Vincent-Salomon, Anne
    Debled, Marc
    Cottu, Paul
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2024, 10 (03):
  • [25] Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis
    Gan, Siyuan
    Dai, Haixia
    Li, Rujia
    Liu, Wang
    Ye, Ruifang
    Ha, Yanping
    Di, Xiaoqing
    Hu, Wenhua
    Zhang, Zhi
    Sun, Yanqin
    GLAND SURGERY, 2020, 9 (03) : 661 - 675
  • [26] Axillary Response to Neoadjuvant Therapy in Node-Positive ER-Positive, HER2-Negative Breast Cancer
    Friedman-Eldar, Orli
    Ozmen, Tolga
    Reyes, Fernando Valle
    Goel, Neha
    Tjendra, Youley
    Kesmodel, Susane B.
    Moller, Mecker
    Franceschi, Dido
    Avisar, Eli
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S236 - S236
  • [27] Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
    Wei Wu
    Jiewen Chen
    Heran Deng
    Liang Jin
    Zhanghai He
    Nanyan Rao
    Yan Nie
    Yandan Yao
    Yaping Yang
    Fengxi Su
    Jieqiong Liu
    BMC Cancer, 21
  • [28] CD133 Expression in ER-positive/HER2-negative Breast Cancer is Prognostic for Survival
    Huang, J.
    Oshi, M.
    Takabe, K.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S57 - S57
  • [29] Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer
    Jung, Wonguen
    Kim, Kyubo
    Moon, Byung-In
    BREAST CARE, 2022, 17 (06) : 561 - 566
  • [30] Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
    Wu, Wei
    Chen, Jiewen
    Deng, Heran
    Jin, Liang
    He, Zhanghai
    Rao, Nanyan
    Nie, Yan
    Yao, Yandan
    Yang, Yaping
    Su, Fengxi
    Liu, Jieqiong
    BMC CANCER, 2021, 21 (01)
12345